Fenwick Represents PinkDX in Second Close of Upsized Series A Financing

Fenwick represented PinkDX, an early-stage company focused on positively impacting the health of women throughout their life journey, in its second close of its previously announced Series A financing, raising an additional $5 million and bringing the total raised to $45 million. The round included new investors Blue Venture Fund, Sandbox Clinical Ventures and BEVC.

PinkDX will use the funds to further advance its first test, which is intended to clarify diagnosis for women presenting with a potential gynecologic cancer. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partners Doug Cogen and Matt Rossiter and included associates Kristen Nicol, Robina Gallagher, and Jonathan Archer.